Discovery Services. Discovery. Biology. Toxicology DMPK. Medicinal Chemistry CADD

Size: px
Start display at page:

Download "Discovery Services. Discovery. Biology. Toxicology DMPK. Medicinal Chemistry CADD"

Transcription

1 Discovery Services Data Flow Biology Medicinal Chemistry Discovery CADD Toxicology DMPK

2 Discovery Services Who we are Sai Life Sciences is a Contract Research, Development and Manufacturing Organization focused on providing innovator pharma companies with drug discovery, CMC development and cgmp commercial scale manufacturing services. Our global pharma and biotech clients gain a clear competitive advantage through shorter time to both progressive development milestones and finally market launch. Synthetic & Medicinal Chemistry Services Sai employs a highly experienced team of over 225 synthetic and medicinal chemists, located in Hyderabad and Pune, to support the varied synthetic and drug discovery needs of our clients. Sai has a 15 year track record of providing high quality and value added chemistry services to > 80 clients from start-ups to big pharma. Biology Services Sai s In vitro pharmacology services include biochemical, cell based and ex-vivo assays. Sai offers In vivo biology models in oncology, inflammation, pain and metabolic disorders. Streamlined coordination with Chemistry, DMPK and Tox teams under the same roof. DMPK Services In vitro DMPK capabilities include metabolism and permeability studies, as well as measurement of various physico/biophysical properties. Sai s In vivo DMPK capabilities include rodent PK and numerous specialized techniques. We have accreditation from multiple international animal welfare agencies (AAALAC, OLAW & CPCSEA). Toxicology Services Non-GLP Toxicology capabilities in rodents include hematology, clinical chemistry, histopathology and toxicokinetics. Genotoxicology capabilities include AMES tests, micronucleus tests, chromosomal aberration tests and cell gene mutation tests. CADD Services We utilize a comprehensive suite of software and hardware to help understand and solve medicinal chemistry problems. We specialize in hit discovery, hit to lead optimization, lead optimization and chemoinformatics. Turbo Tech Transfer Turbo Tech Transfer (T3) is a new value added service Sai introduced to provide rapid access to kg batches of non-gmp drug substance for pre-clinical studies. This expanded service offering compresses the timeline inherent to transferring medchem processes for scale-up. Our goal is to meet your small production requirement, while anticipating the future needs of your program. As your NCE progresses through its initial phases of the molecular lifecycle, the T3 service enables rapid transition to future PR&D services and first in human cgmp batches. 2 discoveryservices@sailife.com

3 Make it Better Together At Sai, developing a business collaboration with our clients that benefits both parties is only the beginning. We have learned through experience, it is when we build a mutually beneficial partnership with a customer, that we can truly add the most value to important pharmaceutical programs. At Sai we will call this make it better together and it points at the additional value we aim to find in a long-term relationship. Amongst the most important elements of a successful partnership are communication and effective program management. To that end, we have built a team with an ingrained culture of supporting our clients and communicating progress. We ve implemented and clearly articulate our program management processes, while continuing to develop tools that better enable us working together for a successful outcome of every project. Website: 3

4 Synthetic & Medicinal Chemistry Services Why Sai? 15 year track record providing high quality and value added chemistry services to > 80 clients from start-ups to big pharma Delivery, flexibility and transparency make Sai a preferred partner for many clients (15 programs advanced to IND filing and beyond) Synthetic experience across a broad range of chemotypes including complex natural products Clear communication via trained project managers equipped with customized reporting tools Robust intellectual property protection via strict compliance policies & systems Availability of erooms and electronic laboratory notebooks Problem solving ability results in delivery of > 95% of all molecules requested Ready access to scientific literature via SciFinder and an extensive collection of journal subscriptions Streamlined coordination with Computational Chemistry, DMPK-Tox and Biology (all teams under one roof) Infrastructure 225 PhD & MS chemists (1 to 4 ratio) in 25 chemistry laboratories across 2 sites 50,000 ft2 of lab space Focused library synthesis lab with automated purification & evaporation Wide range of purification equipment and expertise (mg to kg) Dedicated analytical chemistry support team with key equipment: GCMS LCMS UPLCs SFCs HPLCs (PAD, ELSD & CAD) IR spectrometers UV spectrometers Polarimeters Multi probe NMRs Karl Fisher analyzer Melting point apparatus Thermo-gravimetric analyzer Powder X-ray diffractometer Differential scanning calorimeter Pune Laboratories Hyderabad Laboratories 4 discoveryservices@sailife.com

5 Synthetic Chemistry Capabilities Milligram to kilogram scale synthesis of client-defined compounds Focused compound libraries to support lead generation or optimization Preparation of building blocks, key intermediates and reference compounds Challenging chemotypes (up to 36 steps of targets with multiple stereocenters) Carbohydrates Phosphoramidites Lipids and PEG-chemistry Nucleosides and nucleotides Peptides and oligonucleotides Vitamin D analogues Steroids and prostaglandins Isotopically labeled compounds Drug conjugates (linkers & HPAPIs) Fluorescent & biotinylated compounds Medicinal Chemistry Capabilities Understanding multivariate SAR and problem-solving in lead optimization Rational drug design creating innovative lead compounds by optimizing: Metabolism PK exposure Cell permeability Aqueous solubility herg inhibition CYP & Pgp induction Time dependent & reversible CYP inhibition Potency & selectivity within the biological target class Website: 5

6 Biology Services Why Sai? 4 year track record of providing high quality and value added biology support services across multiple therapeutic areas Comprehensive in vitro and in vivo capabilities Clear and concise reports accompanied by raw data (customized to client requirements) Professional service with emphasis on excellent communication Streamlined coordination with Chemistry and DMPK teams to accelerate progress (all teams under one roof) Flexible and adaptive working style with fast turnaround times Screening throughput of >100 compounds a week per assay Infrastructure Pune Laboratories 15 PhD & MS biologists in Sai s Pune, India laboratories In Vitro Labs: Multimode readers Tecan Infinite M1000 Pro Plate Reader Flexstation 3 Tecan Freedom Evo 100 Liquid Handler Thermo Versette PicoReal qpcr instrument BSL2 cell culture facility Microbiology suite BARC approved radioactive facility In Vivo Labs: AAALAC Approved IVC cage systems Digital Randal Selitto instrument (pain models) Rotarod (motor coordination models) Incapacitance meter Grip strength meter Thermal hyperalgesia hot plate (pain models) Plethysmometer (inflammation assay) Von Frey instrument (pain models) 6 discoveryservices@sailife.com

7 In Vitro Pharmacology Capabilities Biochemical Assays Cell based Assays Protein-protein interaction Cell viability Binding Gene reporter Enzymatic Cytokine release Thermal shift Disease relevant Ex-vivo Assays Imaging Histology Biomarkers Tissue based In Vivo Pharmacology Capabilities Oncology Models Xenograft Syngeneic Metastasis PDX (coming soon) Inflammation Models Arthritis: CIA, CAIA, AIA Skin disorders: psoriasis, PMA-induced, AA-induced Pain Models Nociceptive: hot plate, tail flick, AA writhing, formalin test Neuropathic: CCI, chemo-induced Metabolic Disorder Models Genetic (db/db; ob/ob mice) STZI diabetic neuropathy Zucker fatty rats Website: 7

8 DMPK Services Why Sai? 8 year track record of providing high quality and value added DMPK support to a broad range of clients Accreditation from multiple international animal welfare agencies (AAALAC, OLAW & CPCSEA) Comprehensive in vitro and in vivo capabilities Clear and concise reports accompanied by comprehensive raw data (customized to client requirements) Professional service with emphasis on excellent communication and international logistical support Flexible and adaptive working style with fast turnaround times Streamlined coordination with Chemistry, Formulation, Tox and Biology (all teams under one roof) Infrastructure Pune Laboratories 24 DMPK scientists in Sai s Pune, India laboratories DMPK/bioanalytical equipment and facilities: In Vitro Labs: BARC approved radioactive facility API-4000 LC-MS/MS (2) API-4000 QTRAP LC-MS/MS with PDA UPLC/UV (3) In Vivo Labs: AAALAC, OLAW & CPCSEA approved for rats, mice, rabbits and guinea pigs Institutional Animal Ethics Committee (IAEC) similar to IACUC in USA Continuous and automated monitoring of temperature, humidity and air quality 8 discoveryservices@sailife.com

9 In Vitro DMPK Capabilities Metabolism Permeability CYP profiling PAMPA Metabolite ID Caco-2 Microsomal stability MDCKII / MDR1 Reactive metabolites Transporter studies Stability in hepatocytes Physico / Biophysical Salt form screening Plasma protein binding Pre-formulation development Aqueous and formulation stability Kinetic and thermodynamic solubility In Vivo DMPK Capabilities Rodent PK Mice and rats Plasma Brain Most other tissues Dog PK Beagles (at partner facility) Specialized / Cannulation Techniques Bile duct Portal vein Jugular vein Carotid artery Intraduodenal Enterohepatic recirculation Website: 9

10 Toxicology Services Why Sai? 8 year track record of providing high quality and high value Toxicology support to a broad range of clients Accreditation from multiple international animal welfare agencies (AAALAC, OLAW & CPCSEA) Complete compliance with internal Quality Assurance Unit to ensure integrity of our services and animal studies conducted with strict adherence to SOPs Clear and concise reports accompanied by comprehensive raw data (customized to client requirements) Professional service with emphasis on excellent communication and international logistical support Flexible and adaptive working style with fast turnaround times Streamlined coordination with Chemistry, Formulation, DMPK and Biology (all teams under one roof) Pune Laboratories Infrastructure 8 Toxicologists in Sai s Pune, India laboratories 8,000 ft2 animal facility with 10 isolated suites Laboratory: AAALAC, OLAW & CPCSEA approved for rats, mice, rabbits and guinea pigs Institutional Animal Ethics Committee (IAEC) similar to IACUC in USA Continuous and automated monitoring of temperature, humidity and air quality Bioanalytical Equipment: API-4000 LC-MS/MS (2) API-4000 LC-MS/MS QTRAP with PDA HPLC/UV (3) 10 discoveryservices@sailife.com

11 Non-GLP Toxicology Capabilities Single Dose Mice or rats Oral or parenteral dosing Observations recorded for 7 days post single dose Repeated Dose Hematology Clinical chemistry Histopathology Toxicokinetics Genotoxicology Capabilities AMES Tests Chromosomal Aberration Tests Full Assay Human lymphocytes in vitro Mini Assay Mice bone marrow in vivo Micronucleus Tests Human lymphocytes in vitro Mice lymphocytes in vivo Cell Gene Mutation Test HPRT assay Website: 11

12 CADD Services Why Sai? 5 year track record providing high quality value added computational chemistry services to a broad range of clients Comprehensive suite of software and hardware to help understand and solve medicinal chemistry problems Professional service with an emphasis on excellent communication Flexible and adaptive working style with fast turnaround times Experience in hit discovery, hit to lead optimization, lead optimization and chemoinformatics Associated consultant for Lhasa Limited (chemoinformatics) Infrastructure Graphics Processing Unit (GPU) workstations to support high end simulations and analysis Up to date databases for in silico screening purposes Commercial license to state of the art computational chemistry software: Lhasa Cresset ChemAxon Schrodinger Pipeline Pilot Discovery Studio Pune Laboratories 12 discoveryservices@sailife.com

13 Hit Identification Capabilities Focused library design Fragment based approaches High throughput docking of commercial libraries Virtual screening (focused or commercial databases) Structure and ligand based pharmacophore modeling Lead Optimization Capabilities Scaffold hopping Structure guided optimization SAR & R-group exploration and optimization Flexible docking & molecular dynamic simulations Compound selection based on customized property filters Cheminformatics Capabilities SAR and QSAR analysis ADME prediction modules Virtual library enumeration Medchem database design & maintenance Genotoxic Assessment (ICH-M7 Guidelines) Hepatotoxicity and other toxicity end point predictions Website: 13

14 Turbo Tech Transfer Drug Discovery & T3 in the Molecular Lifecycle Discovery Services Lead Evaluation Synthetic Chemistry Medicinal Chemistry Biology DMPK Top 3 Goals??? Lead Identification & Optimization Triage can comp Toxicology CADD Synthetic & Medicinal Chemists Biology, DMPK & CADD Experts 14 discoveryservices@sailife.com

15 What is T3? Turbo Tech Transfer (T3) is a new value added service Sai introduced to provide rapid access to kg batches of non-gmp drug substance for pre-clinical studies. This expanded service offering compresses the timeline inherent to transferring medchem processes for scale-up. Infrastructure: Focused team combining discovery and scale-up expertise EH&S / HAZOP support Dedicated non-gmp kilo-lab ( 100 L reactors) AR&D (as needed) Capabilities: Scale-up of APIs or scaffolds with minimal or no optimization Utilizing the knowledge and creativity of discovery chemistry merged with the expertise and experience of scale-up chemists Introduction of commercial raw material supplies where applicable Our goal is to meet your small production requirement, while anticipating the future needs of your program. As your NCE progresses through its initial phases of the molecular lifecycle, the T3 service enables rapid transition to future PR&D services and first in human cgmp batches. Turbo Tech Transfer (T3) Candidate Selection Early knowledge building for future development team 1KG 100L potential didate ounds Rapid scale-up of non-gmp tox batches Scaffold scale-ups to support MedChem Identify best candidates Prioritize backup candidates IND-enabling studies Convergent Route Scouting Blended Expertise & Technologies Synthetic, Process, Analytical & Formulation Chemists Tech Transfer & Supply Chain Experts DMPK & Tox Experts Website: 15

16 Website: Designed by Wing Lee Creative

The TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices

The TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices A leading Australian contract research organisation (CRO) providing integrated preclinical drug development services to the biotech and pharmaceutical industries The TetraQ Difference Located at The University

More information

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from

More information

PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016

PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 1 FROM DISCOVERY TO COMMERCIALIZATION At least 10 years on average Average spend of $1.4B Less than 12% of drugs entering Phase I are approved

More information

The Right Molecules. Designed. Delivered.

The Right Molecules. Designed. Delivered. The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered

More information

Optimisation de votre programme de développement

Optimisation de votre programme de développement Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500

More information

Pharmaceutical LC/MS Solutions from Agilent Technologies

Pharmaceutical LC/MS Solutions from Agilent Technologies Pharmaceutical LC/MS Solutions from Agilent Technologies Application Compendium Overview LC/MS plays a key role in the drug discovery and drug development process. Since the introduction of electrospray

More information

Introduction to Drug Development in Commercializing Biomedical Technology

Introduction to Drug Development in Commercializing Biomedical Technology Introduction to Drug Development in Commercializing Biomedical Technology Kevin W. Hunt, Ph.D. Director of Biopharmaceutical Product Development Office of Technology Development and Head of Translational

More information

DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION

DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE XENOGRAFT MODELS DMPK OVERVIEW ADME SUMMARY REPORT DMPK Overview QPS is your Global Link to all your DMPK Sourcing Needs Introduction

More information

Call for Pilot Project Applications Chemical Biology for Infectious Diseases NIH Center of Biomedical Research Excellence University of Kansas

Call for Pilot Project Applications Chemical Biology for Infectious Diseases NIH Center of Biomedical Research Excellence University of Kansas Call for Pilot Project Applications Chemical Biology for Infectious Diseases NIH Center of Biomedical Research Excellence University of Kansas Applications due: Oct 3 rd, 2016 Anticipated Decision Date:

More information

Value Scale (1-5) 1 I. Final Product Profile Characteristics of the product required for patient care

Value Scale (1-5) 1 I. Final Product Profile Characteristics of the product required for patient care In this example, the majority of the compounds was active in the xenograft model and showed "drug-like" properties from in-silico and experimental data. However, the animal studies showed moderate toxicity

More information

Preclinical Drug Development

Preclinical Drug Development Preclinical Drug Development A guidance prepared by From a 2004 NIH Summit Workshop: A major reason for the tremendous cost of drug development is the high rate of drug candidate failure during clinical

More information

PHARMACEUTICAL TESTING

PHARMACEUTICAL TESTING WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey

More information

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report

More information

A full-service CRO with integrated early-stage capabilities

A full-service CRO with integrated early-stage capabilities CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March

More information

SPEED UP YOUR TIME TO MARKET

SPEED UP YOUR TIME TO MARKET SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies

More information

The Aptuit Center for Drug Discovery & Development Verona, Italy

The Aptuit Center for Drug Discovery & Development Verona, Italy The Aptuit Center for Drug Discovery & Development Verona, Italy 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable

More information

Almac Sciences. API Services and Chemical Development: your molecule, our expertise

Almac Sciences. API Services and Chemical Development: your molecule, our expertise Almac Sciences API Services and Chemical Development: your molecule, our expertise About Almac Sciences Almac Sciences is a provider of integrated services from development to commercial scale of advanced

More information

Envigo Corporate & Industry Overview. Rutgers University

Envigo Corporate & Industry Overview. Rutgers University Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1 Who we are Envigo is a global contract research

More information

The Pharmaceutical Technology Specialists.

The Pharmaceutical Technology Specialists. The Pharmaceutical Technology Specialists www.drugdeliveryexperts.com Vision Center of excellence in pharmaceutical, delivery, device technology Incubator of technologies, companies, and talent Provider

More information

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities

More information

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization

More information

Cosmetics Europe LRSS Programme

Cosmetics Europe LRSS Programme Cosmetics Europe LRSS Programme 2016-20 Rob Taalman Objectives of CE Research To deliver tools & strategies for animal-free safety assessment Accurate Robust Efficient ultimately accepted by regulators

More information

Guidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system.

Guidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system. Guidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system. Application for seeking approval of the Central Government for conduct of clinical trial in

More information

Amber Somoza, Technical Services, Gilead San Dimas 21

Amber Somoza, Technical Services, Gilead San Dimas 21 Amber Somoza, Technical Services, Gilead San Dimas 21 Each of the products Gilead researches and develops aligns with therapeutic areas that together impact millions of people in both the developed and

More information

Pharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.

Pharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target

More information

SKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY

SKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY SKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY COMPANY BACKGROUND Specializes in liquid and semi-solid topical products Rx, OTC & Therapeutic

More information

Business Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs

Business Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where

More information

Pharmaceutical Sciences

Pharmaceutical Sciences SRI International Biosciences From Idea to IND Research on Disease Mechanisms Drug Discovery Drug Metabolism, Pharmacokinetics, & Toxicology Services Pharmaceutical Sciences Preclinical Development Planning

More information

Eurofins ADME BIOANALYSES Your partner in drug development

Eurofins ADME BIOANALYSES Your partner in drug development Eurofins ADME BIOANALYSES Your partner in drug development Since 1987, you have placed your confidence in us. Our responsibility, to which my staff and I commit, is to consistently provide you with relevant

More information

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development

More information

BRUSSELS CORDENPHARMA EXPERTS TAKING CARE

BRUSSELS CORDENPHARMA EXPERTS TAKING CARE CORDENPHARMA BRUSSELS EXPERTS TAKING CARE Corden Pharma Brussels S.A. 310 rue de Ransbeek 1120 Brussels Belgium Phone +32 2 263 1411 www.cordenpharma.com/contact-us/ www.cordenpharma.com Our History 1987:

More information

CORDENPHARMA BRUSSELS EXPERTS TAKING CARE

CORDENPHARMA BRUSSELS EXPERTS TAKING CARE CORDENPHARMA BRUSSELS EXPERTS TAKING CARE Our History 1987: Peptisyntha founded by Solvay 1996: First pre-approval FDA inspection for a major peptide made by Peptisyntha for the worldwide market. Following

More information

Our Business. in vitro / in vivo. in vitro / in vivo ADME. in vitro / in vivo. Toxicology. Cell Battery V79. Analytical Services. Service.

Our Business. in vitro / in vivo. in vitro / in vivo ADME. in vitro / in vivo. Toxicology. Cell Battery V79. Analytical Services. Service. GenPharmTox is one of the few CROs who can guarantee the success of our project within the given time framework and on the terms agreed. Dr. Michael Runkel, Apogepha GmbH 3 3 In vitro 3.1. Phototoxicity

More information

Public Interest Incorporated Foundation BioSafety Research Center

Public Interest Incorporated Foundation BioSafety Research Center Public Interest Incorporated Foundation BioSafety Research Center http://www.anpyo.or.jp Ver. 201801 Building #1(Test and research annex) Building #2 (Administrat ion office) Building #3 (Toxicity test

More information

vitro Toxicology Analysis

vitro Toxicology Analysis Anthony D Baxter, CEO New High Content Screening Methods Applied to in vitro Toxicology Analysis Better decisions. Earlier in the game. Enquiries@cyprotex.com Business overview A uniquely packaged ADMET

More information

Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry

Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry Iok- Hou Pang, PhD Pharmaceutical Sciences!! University of North Texas Health Science Center! Outline of Presenta:on

More information

leading the way in research & development

leading the way in research & development leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and

More information

MDI Manufacturing Services

MDI Manufacturing Services MDI Manufacturing Services Presenter, Date Who we are 3M Drug Delivery Systems is a division of 3M dedicated to working together with pharmaceutical and biotech companies to bring new and improved products

More information

Structure and content of an IMPD. What is required for first into man trial?

Structure and content of an IMPD. What is required for first into man trial? What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation

More information

Exclusive Manufacturing Solutions

Exclusive Manufacturing Solutions Exclusive Manufacturing Solutions Helsinn Advanced Synthesis SA Making the difference with highest quality manufacturing facilities, expertise, investments and commitment 1 Index of Contents Building

More information

ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances

ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/142/95 ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE

More information

Agilent RapidFire 360 High-throughput Mass Spectrometry System. Innovative Integrated Technology

Agilent RapidFire 360 High-throughput Mass Spectrometry System. Innovative Integrated Technology Agilent RapidFire 360 High-throughput Mass Spectrometry System Innovative Integrated Technology Agilent RapidFire High-throughput Mass Spectrometry system Streamline workflows and eliminate bottlenecks

More information

S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers

S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of

More information

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical

More information

Recombinant Antibody Production in Therapeutic Antibody Projects. Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016

Recombinant Antibody Production in Therapeutic Antibody Projects. Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016 Recombinant Antibody Production in Therapeutic Antibody Projects Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016 Presentation Outline 1 2 3 4 5 Introduction Recombinant Ab Production

More information

The Five Key Elements of a Successful Metabolomics Study

The Five Key Elements of a Successful Metabolomics Study The Five Key Elements of a Successful Metabolomics Study Metabolomics: Completing the Biological Picture Metabolomics is offering new insights into systems biology, empowering biomarker discovery, and

More information

Guidance for Industry

Guidance for Industry Guidance for Industry ANDAs: Impurities in Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should

More information

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise

More information

Orchid Chemicals & Pharmaceuticals Ltd. A corporate presentation. April

Orchid Chemicals & Pharmaceuticals Ltd. A corporate presentation. April Orchid Chemicals & Pharmaceuticals Ltd. A corporate presentation April 2010 1 Disclaimer This presentation includes forward-looking statements / projections, which are based on current expectations and

More information

Laboratory Reagents. for life science research.

Laboratory Reagents. for life science research. Laboratory Reagents Research, quality control, or routine analysis whatever the field of activity, where there is a need for laboratory reagents, Thermo Fisher Scientific has a suitable product. We offer

More information

Preclinical Development Drugs. Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015

Preclinical Development Drugs. Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015 Preclinical Development Drugs Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015 Product Development: Development process: File Approval Drug Discovery Preclinical Phase 1 Phase 2 Phase 3 Lifecycle

More information

A drug development crossroad lies ahead

A drug development crossroad lies ahead G L O B A L C B O C O S T E F F E C T I V E B I O A N A L Y T I C A L H I G H Q U A L I T Y E A R L Y S T A G E C L I N I C A L T R A N S L A T I O N A L M E D I C I N E H I G H L Y C O M P E T E N T A

More information

Data Requirements for New Chemical Notification in China Please go to for more info about China REACH

Data Requirements for New Chemical Notification in China Please go to  for more info about China REACH Data Requirements for New Chemical Notification in China Please go to http://www.cirs-reach.com/ for more info about China REACH Original Article by Chemical Inspection and Regulation Service (CIRS) in

More information

DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS. September, 2011

DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS. September, 2011 DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS September, 2011 1 CAPRION PROTEOMICS Leading proteomics-based service provider - Biomarker and target discovery

More information

Paracelsus Course Objectives: Toxicology for the Laboratory Animal Scientist. General Toxicology Investigations. Reproductive Toxicology

Paracelsus Course Objectives: Toxicology for the Laboratory Animal Scientist. General Toxicology Investigations. Reproductive Toxicology Toxicology for the Laboratory Animal Scientist CL Davis Foundation Topics in Laboratory Animal Medicine May 7, 2009 Angela King-Herbert, DVM, DACLAM NTP/NIEHS RTP NC Course Objectives: Define terms used

More information

Oral Dosage Formulation Development

Oral Dosage Formulation Development Oral Dosage Formulation Development Achieving faster formulation of solid oral dosage forms for FIH supplies Dr. Colin Lorimer - published April 29, 2011 The pharmaceutical industry is increasingly looking

More information

Case Studies ZoBio

Case Studies ZoBio Case Studies 2011 ZoBio ZoBio Corporate Overview Founded as Dutch BV 11/2004 Full access to all lab facilities of UL Self funded (grants and commercial activities) Doubled income 5 consecutive years 9

More information

The course is taught by a team of UNC faculty and industry scientists. The course has been designed to provide the students an understanding of

The course is taught by a team of UNC faculty and industry scientists. The course has been designed to provide the students an understanding of Drug Metabolism MOPH 810 Fall 2009 Classes: 80 minute class twice a week Course Director: Dhiren R. Thakker Eshelman School of Pharmacy, UNC-Chapel Hill The course is taught by a team of UNC faculty and

More information

COPYRIGHTED MATERIAL. IN THISchapter, we first give definitions of the assay and the bioassay. INTRODUCTION TO ASSAY DEVELOPMENT

COPYRIGHTED MATERIAL. IN THISchapter, we first give definitions of the assay and the bioassay. INTRODUCTION TO ASSAY DEVELOPMENT CHAPTER1 INTRODUCTION TO ASSAY DEVELOPMENT IN THISchapter, we first give definitions of the assay and the bioassay. Drug discovery and development processes are then reviewed to show the role bioassay

More information

Precision. Proficiency. Proximity.

Precision. Proficiency. Proximity. Precision. Proficiency. Proximity. Precision Accuracy in testing is paramount to ensuring product safety and efficacy. And fast turnaround times are critical to keeping your project on schedule. With

More information

Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza

Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza HorizonChem 2018, March, 6th 2018 1 Content Rottapharm Biotech : Company Overview Formulation

More information

Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union

Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction

More information

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects

More information

LC/MS. Why is it the fastest growing analytical technique?

LC/MS. Why is it the fastest growing analytical technique? LC/MS Why is it the fastest growing analytical technique? Discussion topics Evolution of LC/MS Advantages of API Why should I use LC/MS? LC/MS markets Evolution of LC/MS interfaces 1970s to Present Moving

More information

CTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016

CTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016 CTA/NDA Regulatory Landscape in China Jack Xie, PhD, DABT SOT 2016 Disclaimer The content of the following presentation represents solely author s view and may not reflect any position of Roche or China

More information

Harlan Laboratories. Contract Research Services

Harlan Laboratories. Contract Research Services Harlan Laboratories Contract Research Services Table of Contents Overview 2 General Services General Toxicology 3 Reproductive Toxicology in Rats and Rabbits 3 Pathology and Histopathology 4 Genotoxicity

More information

INTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES.

INTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES. 1 INTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES www.lsmuni.lt 2 3 About Lithuanian University of Health Sciences Lithuanian University

More information

Introduction to Assay Development

Introduction to Assay Development Introduction to Assay Development A poorly designed assay can derail a drug discovery program before it gets off the ground. While traditional bench-top assays are suitable for basic research and target

More information

Peptide libraries: applications, design options and considerations. Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST

Peptide libraries: applications, design options and considerations. Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST Peptide libraries: applications, design options and considerations Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST Overview 1 2 3 4 5 Introduction Peptide library basics Peptide library design considerations

More information

OSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward -

OSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward - OSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward - David H. Schubert VP, Regulatory and Quality Outline What? Background and History Who? How? OSWG Committees

More information

Graduate Courses: Advanced Pharmaceutics Prerequisites: Course No: Instructor: Credits: Description:

Graduate Courses: Advanced Pharmaceutics Prerequisites: Course No: Instructor: Credits: Description: The following is a listing of courses offered by the Graduate Program in Pharmaceutical Science. Prerequisites and brief descriptions are included for each course. For more information on a particular

More information

Dr Amy Prosser Careers in Research: Industry

Dr Amy Prosser Careers in Research: Industry www.rsb.org.uk Dr Amy Prosser Careers in Research: Industry @RoyalSocBio #BiologyWeek #RSBcareersDay Careers in Research: Working in the Pharma Industry Dr Amy Prosser My Career History 2011 Completed

More information

Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products

Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Table of contents 1.Introduction...2 2.Scope...3 3.Discussion...4 3.1. Chemistry, manufacturing, and controls...4

More information

Toxicological studies of impurities and degradation products: in silico Methodologies as a safety assessment tool

Toxicological studies of impurities and degradation products: in silico Methodologies as a safety assessment tool Toxicological studies of impurities and degradation products: in silico Methodologies as a safety assessment tool Azeddine Elhajouji, Novartis Institutes for Biomedical Research, Basel, Switzerland 22-Jun-2016

More information

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis

More information

THE INNOVATION COMPANY HEALTH. Institute for Biomedicine and Health Sciences

THE INNOVATION COMPANY HEALTH. Institute for Biomedicine and Health Sciences THE INNOVATION COMPANY HEALTH Institute for Biomedicine and Health Sciences Our central activity is innovative applied research that bridges the gap between basic research and industrial applications.

More information

Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148

Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Request for Proposal Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Dated: October 12 th 2015 Page 1 Table of Contents 1. PURPOSE... 3 2. RFP

More information

drug discovery: Where are we now? How did we RSC February 2013

drug discovery: Where are we now? How did we RSC February 2013 The role of pharmacokinetics in drug discovery: Where are we now? How did we get th here??where are we going? Peter Webborn RSC February 2013 Why conduct PK studies in animals? The primary purpose of pre-clinical

More information

Current practice and future vision on metabolite profiling and quantification in Drug development

Current practice and future vision on metabolite profiling and quantification in Drug development Current practice and future vision on metabolite profiling and quantification in Drug development Geert Mannens EBF Focus workshop Metabolite Profiling and Quantification Strategies in Drug R&D Sept 25,

More information

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities) May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological

More information

Synthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013

Synthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis to Clinic 14 C studies in man a Chemistry perspective Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis-to-Clinic 14 C API synthesis Preclinical Data Regulatory affairs

More information

参考資料. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. Draft

参考資料. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. Draft 参考資料 1 2 3 4 5 Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Draft 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Table of contents 1.

More information

Use of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals

Use of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,

More information

IMPURITIES IN NEW DRUG PRODUCTS

IMPURITIES IN NEW DRUG PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for

More information

Application Note. Kwasi Antwi, Amanda Ribar, Urban A. Kiernan, and Eric E. Niederkofler Thermo Fisher Scientific, Tempe, Arizona

Application Note. Kwasi Antwi, Amanda Ribar, Urban A. Kiernan, and Eric E. Niederkofler Thermo Fisher Scientific, Tempe, Arizona Analysis of an Antibody Drug Conjugate using MSIA D.A.R.T. S. Technology, an Integral Part of Ligand Binding Mass Spectrometric Immunoassay (LB-MSIA) Workflow Application Note Kwasi Antwi, Amanda Ribar,

More information

The Integrated Biomedical Sciences Graduate Program

The Integrated Biomedical Sciences Graduate Program The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to

More information

Laboratory Reagents and Raw Materials for Production.

Laboratory Reagents and Raw Materials for Production. Laboratory Reagents and Raw Materials for Production www.itwreagents.com The Origin of Our Industrial Character ITW Illinois Tool Works Inc. (NYSE: ITW) is a diversified manufacturing company that delivers

More information

Technology Development Funding Program Round 3

Technology Development Funding Program Round 3 Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science

More information

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL Outcomes in Mesenchymal Stem Cell Manufacturing Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL Background HCTL established in 1992 to support BMT programs of Mayo

More information

REIMAGINING DRUG DEVELOPMENT:

REIMAGINING DRUG DEVELOPMENT: Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY

More information

In vitro mechanistic studies on Metabolism-Dependent Inactivation of Cytochrome P450 Enzymes

In vitro mechanistic studies on Metabolism-Dependent Inactivation of Cytochrome P450 Enzymes In vitro mechanistic studies on Metabolism-Dependent Inactivation of Cytochrome P450 Enzymes Brooke Rock, 2016 DDI Conference, Seattle, WA Acknowledgements: PKDM, Amgen, San rancisco Chi-Chi Peng, John

More information

In silico tools to study food-drug interactions, an Industry Perspective

In silico tools to study food-drug interactions, an Industry Perspective Paris, April 4th, 2018 Physiologically Based PharmacoKinetic modeling (PBPK): A new Paradigm in Drug Development In silico tools to study food-drug interactions, an Industry Perspective Neil Parrott, Pharmaceutical

More information

Together to Compete Stefano Manfredini

Together to Compete Stefano Manfredini University of Ferrara Together to Compete Stefano Manfredini Converting research results into economic and social values Creative thinking Invention + ACTIO IOV-ATIO

More information

A Review on Microdosing: Reduction in Cost & Time

A Review on Microdosing: Reduction in Cost & Time Human Journals Review Article June 2016 Vol.:6, Issue:3 All rights are reserved by Rupali Yevale et al. A Review on Microdosing: Reduction in Cost & Time Keywords: Microdosing, phase 0, LC-MS and AMS ABSTRACT

More information

Analytical Methods Development and Validation

Analytical Methods Development and Validation Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the

More information

FDA Perspective on the Preclinical Development of Cancer Vaccines

FDA Perspective on the Preclinical Development of Cancer Vaccines FDA Perspective on the Preclinical Development of Cancer Vaccines Richard D. McFarland Ph.D., M.D. Medical Officer CBER/OCTGT/DCEPT mcfarlandr@cber.fda.gov Cancer Vaccine Clinical Trials Workshop Alexandria,

More information

Adopting Virtual R&D in Drug Development

Adopting Virtual R&D in Drug Development Adopting Virtual R&D in Drug Development 2016 Table of Contents 1. Why virtual R&D? 2. Project management team for drug development 3. Project initiation 4. Clinical study team considerations for virtual

More information

Opportunities for Accelerating Cell Line Development and Beyond

Opportunities for Accelerating Cell Line Development and Beyond Opportunities for Accelerating Cell Line Development and Beyond European CM&C Strategy Forum May 24, 2017 Christopher Frye, Ph.D. Research Advisor & Group Leader Bioprocess R&D Presentation Outline CM&C

More information

Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges

Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory

More information

SMEs in IMI2 Calls for Proposals

SMEs in IMI2 Calls for Proposals SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative

More information